Market closed

Lantheus/$LNTH

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Lantheus

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Ticker

$LNTH
Sector
Health Care
Trading on
NASDAQ

Industry

Health Care Equipment & Supplies
Headquarters
Bedford, United States

Employees

834
Website
www.lantheus.com

Lantheus Metrics

BasicAdvanced
$6.6B
15.72
$6.02
0.51
-

$6.6B

0.51

$126.89

$50.20

841K

1.653

1.525

4.622

52.666

31.23%

17.00%

45.53%

15.72

4.364

5.58

6.96

17.605

24.15%

304.57%

56.59%

127.16%

What the Analysts think about Lantheus

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Lantheus stock.

Lantheus Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Lantheus Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Lantheus News

AllArticlesVideos
Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer's Disease Radiodiagnostic Market

GlobeNewsWire·2 days ago
Lantheus Holdings: Powerhouse Potential In 2025

Lantheus Holdings: Powerhouse Potential In 2025

Seeking Alpha·2 weeks ago
Lantheus Holdings: A Growing Business With Dominant Market Share

Lantheus Holdings: A Growing Business With Dominant Market Share

Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LNTH

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Lantheus stock?

Lantheus (LNTH) has a market cap of $6.6B as of January 15, 2025.

What is the P/E ratio for Lantheus stock?

The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 15.72 as of January 15, 2025.

Does Lantheus stock pay dividends?

No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Lantheus dividend payment date?

Lantheus (LNTH) stock does not pay dividends to its shareholders.

What is the beta indicator for Lantheus?

Lantheus (LNTH) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.